BioWa, Inc. is a New Jersey-based biotech company and a wholly owned subsidiary of Kyowa Kirin Co, Ltd. Established in 2003, BioWa is dedicated to advancing health through innovations in life science and technology, specializing in the out-licensing of Kyowa Kirin's Therapeutic Antibody Technologies, POTELLIGENT and COMPLEGENT. The company's name, BioWa, symbolizes the harmonious fusion of American and Japanese sensibilities, reflecting their earnest mission to enhance the quality of life for all.
As the exclusive worldwide licensor of POTELLIGENT Technology, BioWa offers a proprietary technology that generates fucose-free monoclonal antibodies with significantly increased antibody-dependent cellular cytotoxicity (ADCC), bolstering the immune system's ability to eliminate tumor cells. Additionally, BioWa holds the exclusive global license for COMPLEGENT Technology, a robust platform that enhances complement-dependent cytotoxicity (CDC) of therapeutic antibodies. By combining these technologies, BioWa introduces the AcrretaMab platform, a novel class of antibodies designed to combat various life-threatening diseases, including cancer.
Generated from the website